
RETATRUTIDE 5 MG KIT -5 MG / VIAL -3 VIALS
RETATRUTIDE ā 5 MG KIT (5 MG / VIAL Ć 3VIALS) ā
Ā
š§Ŗ Product Type
Ā
Peptide / Triple Hormonal Receptor Agonist
Ā
Active Ingredient: Retatrutide
Ā
Dosage Form: Lyophilized powder for reconstitution
Ā
Ā
Packaging: 3 vials per kit
Ā
Ā
Ā
š Description
Ā
Ā cutting-edge investigational peptide designed to activate three key hormonal receptors:
Ā
Ā
Ā
GLP-1 (Glucagon-Like Peptide-1)
Ā
GIP (Gastric Inhibitory Polypeptide)
Ā
Glucagon Receptor
Ā
This triple-agonist peptide has demonstrated promising effects in early research studies for its ability to support weight management, enhance insulin sensitivity, and improve metabolic performance. It is intended strictly for laboratory research and non-human use.
Ā
Ā
Ā
š¹ Product Features
Ā
Concentration: 5 MG Retatrutide per vial
Ā
Ā
Ā
Form: Lyophilized peptide (requires reconstitution with bacteriostatic water)
Ā
Storage: Keep refrigerated at 2°Cā8°C after reconstitution
Ā
Purity: High-purity pharmaceutical-grade research peptide
Ā
ā Key Research Benefits
Ā
𧬠Multi-Receptor Activation
Ā
Simultaneously targets GLP-1, GIP & glucagon receptors for synergistic metabolic impact
Ā
š„ Weight Reduction Support
Ā
Helps reduce food intake and increase fat oxidation
Ā
š Glucose & Insulin Modulation
Ā
Promotes improved glycemic control and insulin function
Ā
āļø Energy Balance
Ā
May contribute to increased energy expenditure and metabolic flexibility
Ā
š Suggested Research Use (For Laboratory Purposes Only)
Ā
Retatrutide should be reconstituted with bacteriostatic water prior to subcutaneous administration.
Ā
Ā
Ā
Dosage protocols vary based on study design, species model, and target endpoints.
Ā
Ā
Ā
ā ļø Possible Side Effects (Observed in Research)
Ā
Transient nausea
Ā
GI discomfort
Ā
Appetite suppression
Ā
Injection site redness or swelling
Ā
All effects appear to be dose-dependent and should be monitored throughout the study.
Ā
Ā
Ā
š« Contraindications (For Research Planning)
Ā
Retatrutide is not recommended in research models with:
Ā
Ā
Ā
A history of medullary thyroid carcinoma
Ā
Multiple endocrine neoplasia syndrome type 2 (MEN 2)
Ā
Known hypersensitivity to peptide compounds
Ā
š Purchase & Availability
Ā
For Research Use Only ā Not for Human Consumption
Ā
Format: 5 MG KIT (3 vials Ć 2 MG)
Ā
Ā
Available through certified research suppliers
Ā
Estimated Shipping: 5ā12 business days, depending on region
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
RETATRUTIDE ā 5 MG KIT (5 MG / VIAL Ć 3VIALS) ā
Ā
š§Ŗ Product Type
Ā
Peptide / Triple Hormonal Receptor Agonist
Ā
Active Ingredient: Retatrutide
Ā
Dosage Form: Lyophilized powder for reconstitution
Ā
Ā
Packaging: 3 vials per kit
Ā
Ā
Ā
š Description
Ā
Ā cutting-edge investigational peptide designed to activate three key hormonal receptors:
Ā
Ā
Ā
GLP-1 (Glucagon-Like Peptide-1)
Ā
GIP (Gastric Inhibitory Polypeptide)
Ā
Glucagon Receptor
Ā
This triple-agonist peptide has demonstrated promising effects in early research studies for its ability to support weight management, enhance insulin sensitivity, and improve metabolic performance. It is intended strictly for laboratory research and non-human use.
Ā
Ā
Ā
š¹ Product Features
Ā
Concentration: 5 MG Retatrutide per vial
Ā
Ā
Ā
Form: Lyophilized peptide (requires reconstitution with bacteriostatic water)
Ā
Storage: Keep refrigerated at 2°Cā8°C after reconstitution
Ā
Purity: High-purity pharmaceutical-grade research peptide
Ā
ā Key Research Benefits
Ā
𧬠Multi-Receptor Activation
Ā
Simultaneously targets GLP-1, GIP & glucagon receptors for synergistic metabolic impact
Ā
š„ Weight Reduction Support
Ā
Helps reduce food intake and increase fat oxidation
Ā
š Glucose & Insulin Modulation
Ā
Promotes improved glycemic control and insulin function
Ā
āļø Energy Balance
Ā
May contribute to increased energy expenditure and metabolic flexibility
Ā
š Suggested Research Use (For Laboratory Purposes Only)
Ā
Retatrutide should be reconstituted with bacteriostatic water prior to subcutaneous administration.
Ā
Ā
Ā
Dosage protocols vary based on study design, species model, and target endpoints.
Ā
Ā
Ā
ā ļø Possible Side Effects (Observed in Research)
Ā
Transient nausea
Ā
GI discomfort
Ā
Appetite suppression
Ā
Injection site redness or swelling
Ā
All effects appear to be dose-dependent and should be monitored throughout the study.
Ā
Ā
Ā
š« Contraindications (For Research Planning)
Ā
Retatrutide is not recommended in research models with:
Ā
Ā
Ā
A history of medullary thyroid carcinoma
Ā
Multiple endocrine neoplasia syndrome type 2 (MEN 2)
Ā
Known hypersensitivity to peptide compounds
Ā
š Purchase & Availability
Ā
For Research Use Only ā Not for Human Consumption
Ā
Format: 5 MG KIT (3 vials Ć 2 MG)
Ā
Ā
Available through certified research suppliers
Ā
Estimated Shipping: 5ā12 business days, depending on region












